Although it remains to be seen, President Trump's plan to reduce government regulations by at least 75 percent is causing anxiety for some pharmaceutical executives, according to a Reuters article. They expressed concern for not only the safety of patients, but also that a less robust Food and Drug Administration would make it harder to obtain insurance coverage for expensive new medicines.

The Biotechnology Innovation Organization told Reuters that during discussions with Trump advisors, lobbyists urged the administration not to appoint a new FDA commissioner who would act rashly to speed up the agency’s approval of new medicines.

Executives at more than a dozen pharmaceutical and biotechnology firms agreed, stating that the FDA is already adopting new drug development models, and that a looser review process would put patients at risk, the story said.

Read the full Reuters article